Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug

Dec 15 2023

• By Joseph Haas and Anju Ghangurde

Asia Deal Watch — • Source: Alamy

Related Content

Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal

Mar 21 2023

Stada Grows China Presence Through CR Sanjiu Partnership

Dec 05 2023

Aspen Continues Chinese Voyage By Acquiring Sandoz’s Local Operations

Dec 05 2023

BMS Bets $8.4bn On Biokin’s Bispecific ADC

Dec 12 2023

AstraZeneca Likes What Chinese Innovation Has To Offer

Dec 06 2023

Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction

Nov 29 2023

Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows

Nov 28 2023

Sosei Heptares Eyes $3bn Sales From IBD Drug Returned By GSK

Nov 24 2023

Are Korean Biopharma Alliances Recovering After Gloomy Year?

Nov 21 2023

What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push

Jun 27 2022

Related Companies

Dr. Reddy's Laboratories Ltd.

Coya Therapeutics, Inc.

Merck & Co., Inc.

Boehringer Ingelheim GmbH

Phenomic AI

Astellas Pharma, Inc.

Xyphos Biosciences, Inc.

Eli Lilly and Company

Ohara Pharmaceutical Co., Ltd.

Genentech, Inc.

Merck KGaA

Eisai Co., Ltd.

WuXi Biologics

Oxford Vacmedix UK Limited

SK Bioscience

Hilleman Laboratories Pvt. Ltd.

Connect Biopharma Holdings Ltd.

Simcere Pharmaceutical Group

BeOne Medicines Ltd.

ENSEM Therapeutics

Chiesi Farmaceutici S.p.A.

Additional Topics

Asia Pacific Business Strategies Deals Commercial Deal Watch BioPharmaceutical

More from Deal Watch

More from Deals

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window